278 citations
,
May 2013 in “Ca” This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.
47 citations
,
February 2019 in “Journal of The American Academy of Dermatology” This article reviews the unique health issues and preventive care recommendations for LGBT individuals, emphasizing dermatologic considerations and the importance of culturally competent care, but reports no new clinical findings.
3 citations
,
August 2023 in “Drug safety” This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.
19 citations
,
March 2018 in “Expert Opinion on Drug Safety” In this narrative review, the researchers reported that the overall safety profile of drugs used for treating spondyloarthritis is generally good, with serious adverse events being rare, but emphasized the need for rheumatologists to tailor treatments and closely monitor patients for potential adverse events.
5 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review discusses major dermatologic conditions occurring in the early post-hematopoietic stem cell transplant period and reports no new clinical results; it underscores dermatologists' role in recognizing critical complications.